341 related articles for article (PubMed ID: 34921432)
1. Antibody responses to COVID-19 vaccines in older adults.
Bag Soytas R; Cengiz M; Islamoglu MS; Borku Uysal B; Yavuzer S; Yavuzer H
J Med Virol; 2022 Apr; 94(4):1650-1654. PubMed ID: 34921432
[TBL] [Abstract][Full Text] [Related]
2. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
3. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
Yürüker Ö; Yetkin O; Güvenir M
Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
[TBL] [Abstract][Full Text] [Related]
4. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
[TBL] [Abstract][Full Text] [Related]
5. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
[TBL] [Abstract][Full Text] [Related]
6. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
7. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
10. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
11. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
[TBL] [Abstract][Full Text] [Related]
12. Investigation of SARS-CoV-2 antibody levels after COVID-19 vaccine in chronic hepatitis B patients.
Kinikli S; Afsar FE; Dursun AD; Aksoy A; Karahan G; Cesur S; Hatipoglu ÇA; Ertem GT; Erdinc FS; Urtimur U
Bratisl Lek Listy; 2024; 125(6):376-381. PubMed ID: 38757595
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.
Erdoğan AP; Ekinci F; Akçalı S; Göksel G
J Infect Chemother; 2022 Sep; 28(9):1310-1316. PubMed ID: 35701330
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
16. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older.
Karamese M; Tutuncu EE
J Med Virol; 2022 Jan; 94(1):173-177. PubMed ID: 34427924
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
20. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]